Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PEPD | P12955 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7700224 | 0.80 | ALDH1A1 (0.43) | ALDH1A1L3MBTL1RAB9ASMN1; SMN2HTT | |
| SCHEMBL151570 | 0.75 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1RAB9ASMN1; SMN2PEPD | |
| SCHEMBL2275704 | 0.75 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1RAB9ASMN1; SMN2PEPD | |
| SCHEMBL151569 | 0.75 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1RAB9ASMN1; SMN2PEPD | |
| SCHEMBL16759353 | 0.75 | ALDH1A1 (0.36) | ALDH1A1KMT2APEPD | |
| SCHEMBL23081228 | 0.75 | ALDH1A1 (0.36) | ALDH1A1KMT2APEPD | |
| Hydrochloric Acid SCHEMBL9432225 | 0.73 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1RAB9ASMN1; SMN2PEPD | |
| Ammonia Solution, Strong SCHEMBL5017115 | 0.73 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1RAB9ASMN1; SMN2PEPD | |
| Hydrochloric Acid SCHEMBL9148101 | 0.73 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1RAB9ASMN1; SMN2PEPD | |
| SCHEMBL18283617 | 0.73 | ACE (0.41) | RAB9APEPD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350061-B1 | 2,3-DISUBSTITUTED PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-08-14 | — | — | EP | disclosed |
| US-8357700-B2 | 2,3-disubstituted piperidine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-22 | — | — | US | disclosed |
| US-20110263643-A1 | 2,3-Disubstituted Piperidine Orexin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2011-10-27 | — | — | US | disclosed |
| EP-2350061-A1 | 2,3-DISUBSTITUTED PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010048016-A1 | 2,3-DISUBSTITUTED PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263643-A1 | 2,3-Disubstituted Piperidine Orexin Receptor Antagonists | HCRTR2, HCRTR1, CRHR2 | ALDH1A1 2194/4885L3MBTL1 4418/4885RAB9A 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.